Ipsen Surges on Diversified Growth and Bold 2026 Outlook

PARIS, FRANCE – February 12, 2026 – By Jennifer Anderson

French biopharmaceutical company Ipsen today announced robust financial results for 2025, outperforming expectations and issuing an ambitious forecast for 2026 that signals deep confidence in its strategy of diversification and innovation. The company reported a 10.9% increase in total sales at constant exchange rates, reaching €3.68 billion, driven by powerful growth across its rare disease, oncology, and neuroscience portfolios.

Ipsen's leadership has projected total sales growth to accelerate beyond 13.0% in 2026, a figure that significantly surpasses prior market consensus. This optimistic outlook is underpinned by a flourishing drug pipeline, strategic acquisitions, and an unexpected market advantage for its key drug, Somatuline. The strong performance sent a clear message to investors: Ipsen's pivot towards a diversified portfolio is not just working, it's fueling a new era of growth.

“In 2025, Ipsen delivered strong sales and profit growth,” said David Loew, Chief Executive Officer of Ipsen, in a statement. “We continued to execute across all three therapeutic areas, with a notable performance from Iqirvo. We have advanced multiple pipeline programs and further strengthened our innovation engine through targeted business development.”

Financial Strength and a Surprising Forecast

Ipsen’s financial health in 2025 was marked by across-the-board strength. Core operating income climbed 16.7% to €1.29 billion, boosting the core operating margin to 35.2%. This profitability was powered by exceptional growth in its Rare Disease unit, which saw sales skyrocket by 102.5%, alongside solid gains in Neuroscience (9.7%) and Oncology (4.1%).

The company's guidance for 2026 to deliver sales growth exceeding 13% and maintain a core operating margin above 35% caught the attention of analysts, who had anticipated more modest figures. This confidence stems partly from the performance of its portfolio excluding Somatuline, which collectively grew by 14.2%, but also from a surprising turn of events for Somatuline itself.

The drug, a treatment for acromegaly and neuroendocrine tumors, was expected to face significant pressure from generic competitors. However, Ipsen now anticipates growth for the product in 2026 due to what the company describes as “generic lanreotide production challenges.” This unexpected hurdle for its competitors provides Ipsen with a continued revenue stream from a legacy product, creating a stronger financial cushion to fund its innovation efforts.

The Pipeline Powerhouse

While market dynamics have provided a tailwind, the core of Ipsen's growth story lies in its rapidly advancing and strategically expanded R&D pipeline. The company is anticipating five major regulatory and clinical milestones in 2026, positioning it for a series of potential new revenue streams.

A cornerstone of this strategy was the December 2025 acquisition of ImCheck Therapeutics, a move that significantly bolstered Ipsen's immuno-oncology presence. The prize asset is IPN60340 (ICT01), a first-in-class antibody targeting BTN3A to activate a specific type of T-cell. The drug recently received U.S. FDA Breakthrough Therapy Designation for first-line unfit acute myeloid leukemia (AML), an aggressive blood cancer with high unmet need.

Clinical data has been highly encouraging. In a Phase I/II trial, combining ICT01 with standard-of-care treatment nearly doubled the complete response rate compared to historical data, with a 74% rate in older or unfit patients. These results were seen across various molecular subtypes of AML, including those typically less responsive to treatment, suggesting a broad potential impact.

Beyond the ImCheck acquisition, Ipsen is awaiting several key readouts in 2026:
* Tovorafenib: A European regulatory decision is expected for this treatment for pediatric low-grade glioma.
* Iqirvo (elafibranor): Following a 770% sales surge in 2025, pivotal Phase III data is expected for its use in primary biliary cholangitis, a chronic liver disease.
* Dysport: Pivotal Phase III trial results are anticipated for its use in treating chronic and episodic migraine, potentially opening a massive new market for the well-known neurotoxin.
* IPN10200: Following a successful arbitration win against Galderma that secured Ipsen's rights to its next-generation toxin program, full Phase II data for this long-acting molecule in aesthetic indications are expected to be presented.

This flurry of activity demonstrates a clear strategy to build a portfolio of innovative, high-value medicines. While the company did acknowledge a setback with the failure of its fidrisertib trial for a rare bone disease, the breadth and momentum of the overall pipeline appear more than sufficient to absorb the impact.

A Dual Commitment to Profit and Planet

In parallel with its aggressive commercial and R&D strategy, Ipsen has made notable strides in its corporate sustainability and social responsibility efforts. The company is framing its success not just in financial terms, but also through its impact on patients, employees, and the environment.

In 2025, Ipsen achieved several ambitious environmental targets. It reported a 54% reduction in its direct greenhouse gas emissions (Scopes 1 & 2) from a 2019 baseline and confirmed that 100% of its global electricity now comes from renewable sources. These efforts earned the company a prestigious 'A' rating from the CDP, a non-profit that runs a global environmental disclosure system, placing Ipsen among the top tier of corporations for climate transparency and action.

On the social front, Ipsen announced it has achieved full gender parity within its Executive Leadership Team, a rare accomplishment in the biopharmaceutical industry. Women now also comprise 53% of its Global Leadership Team, demonstrating a tangible commitment to diversity and inclusion at the highest levels of the organization. This dual focus on driving shareholder value while embedding sustainability into its operations showcases a modern approach to corporate leadership that is increasingly valued by investors and the public alike.